SCHEMBL4572103

SCHEMBL4572103

COc1cc(Oc2cccc3cccnc23)nc(Nc2ccc(C#N)cc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 3/20 0.43
HPGDS O60760 1/20 0.43
ABCG2 Q9UNQ0 2/20 0.42
EGLN1 Q9GZT9 2/20 0.41
GLO1 Q04760 2/20 0.41
ACHE P22303 1/20 0.40
CDK4 P11802 1/20 0.39
CDK2 P24941 1/20 0.39
GSK3B P49841 1/20 0.39
KCNH2 Q12809 1/20 0.39
SCN5A Q14524 1/20 0.39
SCN9A Q15858 1/20 0.39
IKBKB O14920 1/20 0.39
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10057776 0.88 MEN1 (0.45) CYP2C9CYP2C19MEN1KMT2AKDM4E
SCHEMBL4572094 0.88 MEN1 (0.49) CYP2C9CYP2C19MEN1KMT2AKDM4E
SCHEMBL10056671 0.85 KCNH2 (0.50) CYP2C9CYP2C19MEN1KMT2AKDM4E
SCHEMBL4568608 0.83 KDM4E (0.43) MEN1KMT2AKDM4EEGLN1LMNA
SCHEMBL8249487 0.73 MEN1 (0.58) CYP2C19MEN1KMT2AKDM4EHPGDS
SCHEMBL13729887 0.72 MEN1 (0.64) CYP2C9CYP2C19MEN1KMT2AKDM4E
SCHEMBL4568606 0.71 KDM4E (0.42) MEN1KMT2AKDM4EACHELMNA
SCHEMBL4568612 0.71 KDM4E (0.43) MEN1KMT2AKDM4EACHELMNA
SCHEMBL31235623 0.69 EGLN1 (0.50) MEN1KMT2AKDM4EHPGDSABCG2
SCHEMBL28617594 0.69 EGLN1 (0.50) MEN1KMT2AKDM4EHPGDSABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809343-B2 Pyrimidine derivative, preparation method and use thereof FUDAN UNIVERSITY (CN) 2014-08-19 US disclosed
US-20120122902-A1 PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF FUDAN UNIVERSITY (CN) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122902-A1 PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF DPYD, TYMP, TYMS CYP2C9 325/4885CYP2C19 160/4885MEN1 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.